Roche Signs a License Agreement with Arrakis Therapeutics for the Discovery of RNA-Targeted Small Molecule Therapies

Shots:

  • Arrakis to receive $190M up front in cash and is eligible to get several billion dollars in pre/clinical and commercial milestones along with royalties for products emerging from the collaboration
  • Arrakis will be responsible for discovery and research activities of each target to a defined point while Roche will get right to exclusively pursue further pre/ clinical development
  • The collaboration will leverage Roche’s rSM discovery platform to discover novel therapies targeting all Roche’s research and development areas

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Business wire